Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255. https://doi.org/10.1002/ijc.25864

Article  CAS  PubMed  Google Scholar 

Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667. https://doi.org/10.1158/1078-0432.CCR-11-1900

Article  CAS  PubMed  Google Scholar 

Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J (2018) Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol 81:195–206. https://doi.org/10.1007/s00280-017-3480-9

Article  CAS  PubMed  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X

Article  CAS  PubMed  Google Scholar 

Kobayashi K, Sugiyama E, Shinozaki E, Wakatsuki T, Tajima M, Kidokoro H, Aoyama T, Nakano Y, Kawakami K, Hashimoto K, Suenaga M, Ichimura T, Ogura M, Chin K, Nakayama I, Ooki A, Takahari D, Suzuki W, Yokokawa T, Minowa Y, Hiraoka T, Suzuki K, Sato H, Hama T, Yamaguchi K (2021) Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol 87:767–777. https://doi.org/10.1007/s00280-021-04237-x

Article  CAS  PubMed  Google Scholar 

Taguchi D, Inoue M, Fukuda K, Yoshida T, Shimazu K, Fujita K, Okuyama H, Matsuhashi N, Tsuji A, Yoshida K, Miura M, Shibata H (2020) Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. Int J Clin Oncol 25:531–540. https://doi.org/10.1007/s10147-019-01593-w

Article  CAS  PubMed  Google Scholar 

Maeda A, Irie K, Ando H, Hasegawa A, Taniguchi H, Kadowaki S, Muro K, Tajika M, Aoki M, Inaguma K, Kajita M, Fujimura A, Fukushima S (2019) Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer Chemother Pharmacol 83:107–113. https://doi.org/10.1007/s00280-018-3710-9

Article  CAS  PubMed  Google Scholar 

Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T (2020) A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). Clin Colorectal Cancer 19:13–21. https://doi.org/10.1016/j.clcc.2019.10.004

Article  PubMed  Google Scholar 

Fukudo M, Asai K, Tani C, Miyamoto M, Ando K, Ueno N (2021) Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Invest New Drugs 39:1422–1431. https://doi.org/10.1007/s10637-021-01115-4

Article  CAS  PubMed  Google Scholar 

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558. https://doi.org/10.1200/JCO.2014.57.9151

Article  PubMed  Google Scholar 

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O (2015) Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs 33:1257–1262. https://doi.org/10.1007/s10637-015-0292-9

Article  CAS  PubMed  Google Scholar 

Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M (2019) Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncol 97:277–285. https://doi.org/10.1159/000501281

Article  CAS  Google Scholar 

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M (2019) Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers (Basel) 11:952. https://doi.org/10.3390/cancers11070952

Article  CAS  PubMed  Google Scholar 

Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, Takahashi T, Kiyama S, Kobayashi R, Yoshida K, Suzuki A (2021) Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. Int J Clin Oncol 26:1257–1263. https://doi.org/10.1007/s10147-021-01910-2

Article  CAS  PubMed  Google Scholar 

Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G (2017) Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. Biochem Pharmacol 129:85–95. https://doi.org/10.1016/j.bcp.2017.01.002

Article  CAS  PubMed  Google Scholar 

Stivarga tabletsR [package insert on the internet]. Bayer Yakuhin (2022) https://pharma-navi.bayer.jp/sites/g/files/vrxlpx9646/files/2022-12/STI_MPI_202212230.pdf, accessed Jan 30, 2024

Fujita K, Miura M, Shibata H (2016) Quantitative determination of regorafenib and its two major metabolites in human plasma with high-performance liquid chromatography and ultraviolet detection. Biomed Chromatogr 30:1611–1617. https://doi.org/10.1002/bmc.3730

Article  CAS  PubMed  Google Scholar 

Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A (2022) Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. Eur J Cancer 168:99–107. https://doi.org/10.1016/j.ejca.2022.03.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter NJ (2014) Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging 31:67–78. https://doi.org/10.1007/s40266-013-0140-6

Article  CAS  PubMed  Google Scholar 

Pang YY, Tan YL, Ho HK (2017) Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 1061–1062:220–224. https://doi.org/10.1016/j.jchromb.2017.07.023

Article  CAS  PubMed  Google Scholar 

Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA (2020) Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol 86:2362–2376. https://doi.org/10.1111/bcp.14334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Q, Chen M, Anderson JT, Sun X, Hu S, Sparreboom A, Baker SD (2019) Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice. Clin Transl Sci 12:400–407. https://doi.org/10.1111/cts.12630

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM (2014) Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int 85:1434–1443. https://doi.org/10.1038/ki.2013.517

Article  CAS  PubMed  Google Scholar 

Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP et al (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333:1171–1175. https://doi.org/10.1056/NEJM199511023331802

Article  CAS  PubMed  Google Scholar